))
#27 – Greg Divis, CEO Of Avadel Pharmaceuticals
Manage episode 392373333 series 3478706
Content provided by Slice of Healthcare LLC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Slice of Healthcare LLC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Join us on the latest episode! Our Guest: Greg Divis, CEO at Avadel Pharmaceuticals
What you'll get out of this episode:
- Discussing LUMRYZ, a new narcolepsy drug.
- Insights into the challenges of narcolepsy treatment.
- Avadel's future plans in healthcare innovation.
To learn more about Greg and Avadel Pharmaceuticals:
Guest LinkedIn: https://www.linkedin.com/in/greg-divis-a525334/
Website: https://www.avadel.com/
Company LinkedIn: https://www.linkedin.com/company/avadelpharmaceuticals/
Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/
BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/
45 episodes
Share
